Tesamorelin: A Comprehensive Research Overview of the GHRH Analogue

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), consisting of 44 amino acids with the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂. It has a molecular weight of approximately 5,135.78 Da and a CAS number of 218949-48-5.

The compound is structurally identical to endogenous GHRH(1-44) with one critical modification: the addition of a trans-3-hexenoic acid moiety at the N-terminus. This lipophilic modification protects the molecule from enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), significantly extending its biological half-life compared to native GHRH. Tesamorelin is typically supplied as a white lyophilised powder that is freely soluble in water.

Developed by Theratechnologies Inc. of Montreal, Canada, tesamorelin was approved by the US Food and Drug Administration (FDA) in November 2010 under the brand name Egrifta — making it the first and, to date, only medication approved in the United States specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. An updated concentrated formulation (Egrifta WR, designated F8) received FDA approval in March 2025.

For research use only. Not intended for human or veterinary use.

Mechanism of Action: The GHRH–GH–IGF-1 Axis

Tesamorelin exerts its primary effects through selective activation of the GHRH receptor (GHRH-R), a G protein-coupled receptor (GPCR) expressed on somatotroph cells of the anterior pituitary gland. Upon binding, tesamorelin triggers a Gs-coupled adenylate cyclase signalling cascade that increases intracellular cyclic adenosine monophosphate (cAMP) levels. This cAMP accumulation activates protein kinase A (PKA), which in turn promotes the transcription, synthesis, and pulsatile secretion of endogenous growth hormone (GH) from the pituitary.

This mechanism is fundamentally different from exogenous GH administration. Rather than introducing supraphysiological levels of recombinant GH directly into the circulation, tesamorelin stimulates the body's own GH production through the natural hypothalamic–pituitary axis. The result is pulsatile GH release that more closely mirrors the endogenous secretory pattern — a distinction that researchers consider important because pulsatility is thought to play a role in maintaining normal tissue responsiveness to GH signalling.

Once released, GH acts on hepatocytes and other target tissues to stimulate the production of insulin-like growth factor 1 (IGF-1). The GH–IGF-1 axis mediates many of the downstream metabolic effects observed in tesamorelin research, including changes in lipid metabolism, body composition, and hepatic fat content.

The trans-3-hexenoic acid modification at the N-terminus is central to tesamorelin's pharmacological profile. Native GHRH(1-44) is rapidly cleaved by DPP-IV at the Tyr¹-Ala² bond, yielding inactive fragments with a plasma half-life of only a few minutes. The hexenoic acid cap sterically hinders this cleavage, extending the functional half-life and enabling once-daily dosing in clinical studies.

Visceral Adipose Tissue Reduction: The Landmark Clinical Evidence

Phase 3 Trials in HIV-Associated Lipodystrophy

The clinical development of tesamorelin centred on its capacity to reduce visceral adipose tissue (VAT) in people living with HIV who had developed lipodystrophy — a condition characterised by abnormal fat redistribution, particularly the accumulation of deep abdominal fat, as a consequence of long-term antiretroviral therapy.

In the pivotal Phase 3 confirmatory trial, HIV-positive patients on stable antiretroviral therapy were randomised to receive either tesamorelin 2 mg or placebo by daily subcutaneous injection for 26 weeks. The primary endpoint was change in VAT as measured by CT imaging. Tesamorelin-treated patients demonstrated a statistically significant reduction in visceral fat compared to placebo, with improvements in waist circumference and trunk fat also observed.

JAMA 2014: Visceral Fat and Liver Fat

A landmark randomised clinical trial published in JAMA by Stanley and colleagues (2014) provided further evidence of tesamorelin's metabolic effects. In this study of 48 HIV-infected patients with abdominal fat accumulation, tesamorelin administered for six months was associated with a mean reduction in visceral adipose tissue of −34 cm² (95% CI: −53 to −14 cm²). The study also reported modest but notable reductions in liver fat content — a finding that would later prompt dedicated investigation into tesamorelin's hepatic effects.

Importantly, the researchers noted that visceral fat reaccumulated after discontinuation of treatment, suggesting that the compound's effects on adipose tissue are maintained only during active administration — a finding consistent with its mechanism of augmenting endogenous GH pulsatility rather than inducing permanent structural changes.

Hepatic Fat and NAFLD: Emerging Research

Lancet HIV 2019: Liver Fat Reduction

One of the most significant recent developments in tesamorelin research has been the investigation of its effects on non-alcoholic fatty liver disease (NAFLD). A randomised, double-blind, multicentre trial published in The Lancet HIV by Stanley and colleagues (2019) demonstrated that tesamorelin significantly reduces liver fat content in men and women with HIV and NAFLD. The study further showed that tesamorelin substantially attenuated the high rate of hepatic fibrosis progression observed in the placebo group — a finding with potentially important implications given the elevated prevalence of NAFLD among people living with HIV.

JCI Insight 2020: Hepatic Transcriptomics

Building on these findings, Fourman and colleagues (2020) published a hepatic transcriptomic analysis in JCI Insight examining the molecular mechanisms underlying tesamorelin's liver effects. Over a one-year treatment period, tesamorelin significantly reduced liver fat and prevented fibrosis progression. The transcriptomic data revealed that tesamorelin modulated gene expression pathways involved in lipid metabolism, inflammation, and fibrogenesis — providing mechanistic insight into how augmented GH signalling may protect against hepatic steatosis and its progression.

A Phase II clinical trial (NCT07481734, registered 2026) is currently investigating tesamorelin for the reduction of liver fat in adults with fatty liver disease outside the HIV population, reflecting growing interest in the compound's hepatoprotective potential in broader metabolic contexts.

Muscle Composition and Body Composition Effects

Beyond its well-characterised effects on visceral and hepatic fat, tesamorelin has been studied for its impact on skeletal muscle quality and quantity. An exploratory secondary analysis published in The Journal of Frailty & Aging by Adrian and colleagues (2018) examined CT-derived muscle data from 193 tesamorelin responders and 148 placebo participants.

The analysis revealed that 26 weeks of tesamorelin treatment was associated with significantly greater increases in muscle density — indicating reduced intramuscular fat — across all four truncal muscle groups examined (rectus abdominis, anterolateral abdominal, psoas major, and paraspinal muscles; all p < 0.005). The largest net increase was observed in the rectus abdominis, with a gain of 3.5 Hounsfield units compared to placebo.

Tesamorelin was also associated with significant increases in lean muscle area across all four muscle groups. In multivariate analyses adjusting for changes in IGF-1, the effects on lean muscle area remained significant for the rectus and paraspinal muscles, suggesting that tesamorelin's muscle-related effects may be partially mediated through the GH–IGF-1 axis but also involve additional mechanisms.

These findings are particularly relevant in the context of ageing research, where the simultaneous reduction of visceral fat and preservation or improvement of lean muscle mass represents a desirable but difficult-to-achieve metabolic outcome.

Cognitive Function: Preclinical and Clinical Observations

An intriguing area of tesamorelin research involves its potential effects on cognitive function. A randomised controlled trial presented at the Alzheimer's Association International Conference and reported in Nature Reviews Endocrinology (2012) found that 20 weeks of daily tesamorelin administration improved executive function in both healthy older adults and those with mild cognitive impairment (MCI).

The proposed mechanism involves the restoration of IGF-1 levels to those typical of younger adults. IGF-1 receptors are widely expressed in the hippocampus and prefrontal cortex — brain regions critical for memory consolidation and executive function — and preclinical studies have demonstrated that IGF-1 signalling supports neuronal survival, synaptic plasticity, and neurogenesis.

A more recent study published in The Journal of Infectious Diseases (2025) examined the effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. The tesamorelin group showed a trend toward improved neurocognitive performance after six months of treatment (mean change 0.146; 95% CI: −0.002 to 0.294), though the results did not reach conventional statistical significance — likely reflecting the small sample size and heterogeneity of cognitive outcomes in this population.

While these findings remain preliminary, they have generated considerable interest in the potential role of GHRH-axis modulation in age-related cognitive decline and warrant further investigation in larger, dedicated trials.

Metabolic Profile and Lipid Effects

The metabolic effects of tesamorelin extend beyond changes in body composition. A pivotal study published in the New England Journal of Medicine by Falutz and colleagues (2007) demonstrated that 26 weeks of daily tesamorelin decreased visceral fat and improved lipid profiles in HIV-infected patients. Specifically, tesamorelin was associated with reductions in triglyceride levels and improvements in the trunk-to-limb fat ratio — a marker of the lipodystrophic fat redistribution pattern.

A comprehensive 2026 systematic review by Badran and colleagues confirmed that tesamorelin produces significant reductions in visceral fat accompanied by a more favourable safety profile than exogenous GH administration. The review also noted improvements in lean body mass and IGF-1 levels, with the authors concluding that tesamorelin's mechanism of stimulating endogenous pulsatile GH release may confer metabolic advantages over direct GH replacement.

Safety and Tolerability

Across clinical trials, tesamorelin has demonstrated a generally favourable safety profile. The most commonly reported adverse effects include arthralgia (joint pain), mild peripheral oedema, injection-site reactions (erythema, pruritus), and musculoskeletal discomfort. These effects are consistent with the known pharmacology of GH-axis stimulation and are typically mild to moderate in severity.

Because tesamorelin increases endogenous GH and IGF-1 levels, monitoring for glucose intolerance is recommended during treatment. Some studies have reported modest increases in fasting glucose and HbA1c, though clinically significant diabetes has not been a prominent finding in the published literature. The FDA labelling for Egrifta advises caution in patients with pre-existing glucose intolerance or diabetes.

It is worth noting that the effects of tesamorelin on visceral fat and metabolic parameters are reversible upon discontinuation — visceral fat reaccumulates and IGF-1 levels return to baseline — which has implications for the design of long-term research protocols.

Summary

Tesamorelin represents a pharmacologically distinct approach to modulating the GH–IGF-1 axis. By augmenting endogenous pulsatile GH secretion rather than replacing it with exogenous hormone, tesamorelin produces a metabolic profile that includes visceral fat reduction, hepatic fat attenuation, improvements in muscle composition, and potentially beneficial effects on cognitive function — all while maintaining a safety profile that compares favourably to direct GH administration.

The compound's journey from a GHRH analogue designed to treat HIV-associated lipodystrophy to a research tool with potential applications in NAFLD, sarcopenia, and cognitive ageing reflects the broader scientific interest in the GH–IGF-1 axis as a therapeutic target. As ongoing and future clinical trials continue to explore tesamorelin's effects in non-HIV populations, the compound remains one of the most extensively studied GHRH analogues in the current research landscape.

References

1. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389.

2. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV. 2019;6(12):e821-e830.

3. Fourman LT, Billingsley JM, Engelman A, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134.

4. Adrian S, Scherzinger A, Sanyal A, et al. The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging. 2019;8(3):154-159.

5. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.

6. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: a systematic review. Obes Res Clin Pract. 2026.

7. Vitiello MV, Moe KE, Merriam GR, et al. Growth hormone releasing hormone improves the cognition of healthy older adults and those with mild cognitive impairment. Alzheimer's & Dementia. 2011;7(4):S555.

8. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.

Disclaimer: This article is intended for educational and research purposes only. It does not constitute medical advice. All compounds discussed are for laboratory research use only and are not approved for human consumption outside of regulated clinical settings.